Review



β mercaptoethanol  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MedChemExpress β mercaptoethanol
    β Mercaptoethanol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/β mercaptoethanol/product/MedChemExpress
    Average 90 stars, based on 3 article reviews
    β mercaptoethanol - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    β mercaptoethanol  (MedChemExpress)
    90
    MedChemExpress β mercaptoethanol
    β Mercaptoethanol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/β mercaptoethanol/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    β mercaptoethanol - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    malic acid  (MedChemExpress)
    90
    MedChemExpress malic acid
    Malic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/malic acid/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    malic acid - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    dlin mc3 dma mc3  (MedChemExpress)
    90
    MedChemExpress dlin mc3 dma mc3
    Lipid components of LNPs. We prepared three SS-OP LNPs and three <t> MC3 </t> LNPs, containing 10 mol%, 20 mol% and 40 mol% of cholesterol, respectively. Here we showed the lipid components of each LNP and their mRNA encapsulation efficacy (%). Data are represented as mean ± SD (n = 3).
    Dlin Mc3 Dma Mc3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dlin mc3 dma mc3/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    dlin mc3 dma mc3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    titratable acids  (MedChemExpress)
    90
    MedChemExpress titratable acids
    Lipid components of LNPs. We prepared three SS-OP LNPs and three <t> MC3 </t> LNPs, containing 10 mol%, 20 mol% and 40 mol% of cholesterol, respectively. Here we showed the lipid components of each LNP and their mRNA encapsulation efficacy (%). Data are represented as mean ± SD (n = 3).
    Titratable Acids, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/titratable acids/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    titratable acids - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Lipid components of LNPs. We prepared three SS-OP LNPs and three MC3 LNPs, containing 10 mol%, 20 mol% and 40 mol% of cholesterol, respectively. Here we showed the lipid components of each LNP and their mRNA encapsulation efficacy (%). Data are represented as mean ± SD (n = 3).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: Lipid components of LNPs. We prepared three SS-OP LNPs and three MC3 LNPs, containing 10 mol%, 20 mol% and 40 mol% of cholesterol, respectively. Here we showed the lipid components of each LNP and their mRNA encapsulation efficacy (%). Data are represented as mean ± SD (n = 3).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: Encapsulation

    Physicochemical property of mRNA-LNPs. The particle size and polydispersity index (PDI) of SS-OP LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol. These closed bars mean the size of mRNA-LNPs. These dots mean the PDI of mRNA-LNPs (Left). The particle size and PDI of MC3 LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol. These closed bars mean the size of mRNA-LNPs. These dots mean the PDI of mRNA-LNPs (Right). Data are represented as mean ± SD (n = 3–4).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: Physicochemical property of mRNA-LNPs. The particle size and polydispersity index (PDI) of SS-OP LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol. These closed bars mean the size of mRNA-LNPs. These dots mean the PDI of mRNA-LNPs (Left). The particle size and PDI of MC3 LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol. These closed bars mean the size of mRNA-LNPs. These dots mean the PDI of mRNA-LNPs (Right). Data are represented as mean ± SD (n = 3–4).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques:

    The zeta potential of mRNA-LNPs. We prepared three SS-OP LNPs and three MC3 LNPs, containing 10 mol%, 20 mol%, and 40 mol% of cholesterol, respectively. Here we showed the zeta potential of mRNA-LNPs (mV). Data are represented as mean ± SD (n = 3).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: The zeta potential of mRNA-LNPs. We prepared three SS-OP LNPs and three MC3 LNPs, containing 10 mol%, 20 mol%, and 40 mol% of cholesterol, respectively. Here we showed the zeta potential of mRNA-LNPs (mV). Data are represented as mean ± SD (n = 3).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: Zeta Potential Analyzer

    The one-week stability of mRNA-LNPs . All LNPs were tested at 0, 1, 3, and 7 days after the preparation while they were stored at 4°C. (A) The mRNA encapsulation efficacy of SS-OP LNPs (Left) and MC3 LNPs (Right). Data are represented as mean ± SD for encapsulation efficacy (n = 3–4). (B) The particle size of SS-OP LNPs (Left) and MC3 LNPs (Right). (C) The PDI of SS-OP LNPs (Left) and MC3 LNPs (Right). Data are represented as mean ± SD for particle size and PDI (n = 3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test. * P < 0.05, between Day 0 and Day 7 of SS-OP LNPs containing 10mol% cholesterol groups.

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: The one-week stability of mRNA-LNPs . All LNPs were tested at 0, 1, 3, and 7 days after the preparation while they were stored at 4°C. (A) The mRNA encapsulation efficacy of SS-OP LNPs (Left) and MC3 LNPs (Right). Data are represented as mean ± SD for encapsulation efficacy (n = 3–4). (B) The particle size of SS-OP LNPs (Left) and MC3 LNPs (Right). (C) The PDI of SS-OP LNPs (Left) and MC3 LNPs (Right). Data are represented as mean ± SD for particle size and PDI (n = 3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test. * P < 0.05, between Day 0 and Day 7 of SS-OP LNPs containing 10mol% cholesterol groups.

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: Encapsulation

    In vitro transfection efficiency of mRNA-LNPs . The luciferase expression levels of HepG2 cells transfected by using SS-OP LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol (Left) and MC3 LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol (Right). Data are represented as mean + SD (n = 3). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: In vitro transfection efficiency of mRNA-LNPs . The luciferase expression levels of HepG2 cells transfected by using SS-OP LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol (Left) and MC3 LNPs containing 10 mol%, 20 mol%, and 40 mol% of cholesterol (Right). Data are represented as mean + SD (n = 3). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: In Vitro, Transfection, Luciferase, Expressing

    In vivo transfection efficiency of mRNA-LNPs by intramuscular administration. Transfection efficiency of SS-OP LNPs (A) and MC3 LNPs (B) by intramuscular administration. Mice were intramuscularly administrated with luciferase mRNA LNPs, containing 10 mol%, 20 mol%, 40 mol% cholesterol. Four and a half h after administration, luciferase expression levels were analyzed in the muscle and the liver (n=3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05). Data are represented as mean + SD (n=3–4).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: In vivo transfection efficiency of mRNA-LNPs by intramuscular administration. Transfection efficiency of SS-OP LNPs (A) and MC3 LNPs (B) by intramuscular administration. Mice were intramuscularly administrated with luciferase mRNA LNPs, containing 10 mol%, 20 mol%, 40 mol% cholesterol. Four and a half h after administration, luciferase expression levels were analyzed in the muscle and the liver (n=3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05). Data are represented as mean + SD (n=3–4).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: In Vivo, Transfection, Luciferase, Expressing

    In vivo transfection efficiency of mRNA-LNPs by subcutaneous administration. Transfection efficiency of SS-OP LNPs (A) and MC3 LNPs (B) by subcutaneous administration. Mice were subcutaneously administrated with luciferase mRNA-LNPs, containing 10 mol%, 20 mol%, 40 mol% cholesterol. Four and a half h after administration, luciferase expression levels were analyzed in the muscle and the liver (n=3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05). Data are represented as mean + SD (n=3–4).

    Journal: Journal of Pharmaceutical Sciences

    Article Title: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

    doi: 10.1016/j.xphs.2022.12.026

    Figure Lengend Snippet: In vivo transfection efficiency of mRNA-LNPs by subcutaneous administration. Transfection efficiency of SS-OP LNPs (A) and MC3 LNPs (B) by subcutaneous administration. Mice were subcutaneously administrated with luciferase mRNA-LNPs, containing 10 mol%, 20 mol%, 40 mol% cholesterol. Four and a half h after administration, luciferase expression levels were analyzed in the muscle and the liver (n=3–4). Statistical analysis was performed by one-way ANOVA Tukey's multiple comparisons test (* P < 0.05). Data are represented as mean + SD (n=3–4).

    Article Snippet: Cholesterol was purchased from Nacalai Tesque, Inc. (Kyoto, Japan); 1,2-Distearoyl-sn-glycerol-3- phosphocholine (DSPC) from Avanti Polar Lipids, Inc. (Alabaster, AL); DLin-MC3-DMA (MC3) from MedChemExpress (Monmouth Junction, NJ); DL-malic acid from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan); NucleoSpin Plasmid Transfection Grade from MACHEREY-NAGEL GmbH & Co. (KG, Germany); Sap I restriction enzyme and HiScribe T7 High Yield RNA Synthesis Kit from New England BioLabs, Inc.(Beverly, MA, USA); DNase TURBO from Life Technologies (Carlsbad, CA); CleanCap® Reagent AG from TriLink BioTechnologies (San Diego, CA); 2-(N-morpholino)ethanesulfonic acid (MES) from DOJINDO LABORATORIES (Kumamoto, Japan); and Quanti-iT TM RiboGreen RNA reagent from Molecular Probes (Eugene, OR).

    Techniques: In Vivo, Transfection, Luciferase, Expressing